Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2016

View Archived Issues

BioMed X and J&J to develop biofilm inhibitors for oral health applications

ChemoCentryx provides update on CCX-168

Verastem initiates phase I trial of defactinib, pembrolizumab and gemcitabine in pancreatic cancer

SolaranRx enters into CRADA with NCI to advance metastatic melanoma theranostic

Peregrine and NCCN establish research collaboration to advance development of bavituximab

C4 Therapeutics launches from Dana-Farber, enters collaboration with Roche

Principia advances two programs in clinic

ViiV Healthcare and Janssen to collaborate to develop rilpivirine and cabotegravir regimen

Gilead reports topline data from phase III studies of tenofovir alafenamide in chronic HBV

uniQure reports on low-dose cohort in phase I/II hemophilia B trial of AMT-060

X-Chem forms discovery collaboration with Sanofi

Checkpoint Therapeutics to obtain rights to Teva's oral PARP inhibitor

Aridis reports promising phase I data on Aerucin

Gruenenthal discloses CRAC blockers

NKTT-120 reduces iNKT cells in patients with sickle cell disease

Bayer Schering Pharma reports BRD4 inhibitors

The University of Montana presents SLC7A11 inhibitors

Johnson & Johnson Innovation discloses a plethora of new collaborations

XBiotech reports data from phase III European trial of Xilonix

AbbVie begins phase III program evaluating ABT-494 for rheumatoid arthritis

Gruenenthal and Akashi Therapeutics form joint drug development program for HT-100

PSMA-targeted ACCURIN shows promise for mCRPC

ImaginAb presents data on PSMA imaging agent for diagnosis of prostate cancer

PTC Therapeutics completes rolling NDA for Translarna, submits phase III data to EMA

FDA grants orphan drug designation to components of Immune Design's CMB-305

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...